The forecast for cardiac glycosides sales in Canada indicates a declining trend from 2024 through 2028. Starting at 13.3 million CAD in 2024, sales are projected to decrease to 11.8 million CAD by 2028. For context, sales were more robust in 2023, exemplifying the forthcoming decline. Year-on-year variations show a steady decrease, with an overall compound annual growth rate (CAGR) that highlights an average annual reduction over the five-year period.
Future trends to watch for include:
- Innovations in treatment that could reduce reliance on cardiac glycosides.
- Shifts in healthcare policies impacting drug prescription dynamics.
- Potential regulatory changes affecting market dynamics.
